Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

NASH: Non-invasive Diagnostic Markers and Imaging

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02717000
Recruitment Status : Unknown
Verified March 2016 by Ger Koek, Maastricht University Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : March 23, 2016
Last Update Posted : March 23, 2016
Sponsor:
Collaborator:
Zuyderland Medical Centre
Information provided by (Responsible Party):
Ger Koek, Maastricht University Medical Center

Brief Summary:

Rationale:

Non-alcoholic fatty liver disease (NAFLD) is the most widespread liver disorder in Western society (prevalence 20-30%). It is strongly associated with overweight and obesity. The majority of patients have simple steatosis. However, in about 15-30% of the subjects, a chronic inflammatory state develops that is referred to as non-alcoholic steatohepatitis (NASH), which leads to an overall increase in morbidity and mortality due to the progression to fibrosis, cirrhosis and in some cases, hepatocellular carcinoma (HCC). The term NAFLD comprises both simple steatosis and NASH. Most patients with NAFLD have no or few, mainly aspecific symptoms; and generally there is a silent progression of simple steatosis to NASH and in the end, liver-related morbidity and mortality.

To date, liver biopsy is the most sensitive test for detecting and staging NAFLD, and is the only reliable method for differentiating between NASH and simple steatosis. However, the procedure of obtaining a liver biopsy is invasive and associated with patient discomfort, significant complications and high costs. In addition, liver biopsy is prone to sampling error and inter- and intra-observer variability, due to the small size of liver biopsy samples. This method is therefore not suitable for screening large numbers of subjects at risk, or for follow-up of patients with NASH over time. Hence, only subjects at high risk (usually based upon elevated aminotransferase levels, which is not specific for the presence of NASH) are biopsied, leading to an underestimation of NASH prevalence and undertreatment. Further insight into disease mechanisms and risk factors for NAFLD and in particular NASH is warranted, to enable early diagnosis, adequate therapy and preventive measures to improve health status of these individuals. Accurate and less invasive methods to evaluate NASH, and NAFLD, are urgently needed.

Objective: The primary objective of this study is to establish non-invasive tools (e.g. biomarkers and imaging) to accurately diagnose patients with NASH. The secondary objective is to show an association between the levels of identified markers and disease severity.

Study design:

Eligible subjects will be included via the outpatient clinics Zuyderland in Heerlen, the Catharina hospital in Eindhoven and MUMC+ in Maastricht. A subset of eligible subjects has undergone a liver biopsy for clinical reasons. It is estimated that about 85% of subjects will be asked to undergo a biopsy for study purposes only. Liver biopsies for study purposes will be performed during a surgical procedure, e.g. bariatric surgery or cholecystectomy.

Blood, faeces and exhaled air will be collected and a FibroScan (+CAP) will be performed during a study visit. An MRI will be performed, to estimate the degree of steatosis. Furthermore, anthropometric data (weight, height, abdominal and waist circumference and blood pressure (BP)) will be collected.

The participants in the group undergoing liver biopsy during bariatric surgery will be asked permission to be approached for follow-up measurements 3 months post-surgery. As they will lose weight, which is associated with improvement of hepatic steatosis, this enables assessment of possible changes over time. A routine follow-up visit post-surgery will take place after 3 months. The follow-up measurements will be combined with this visit, minimizing the burden for the participant. The measurements will consist of blood, faeces and exhaled air collection and a FibroScan (+CAP) will be performed during a study visit. Furthermore, weight, height, BP and abdominal and waist circumference will be measured.

Study population:

Subjects with proven NAFLD by histology or NAFLD proven by imaging, who are undergoing surgery (i.e. bariatric surgery or cholecystectomy) will be asked to participate in this study. Furthermore, all subjects have to be between 18 and 65 years old.

Main study parameters/endpoints:

Non-invasive tool based on biomarkers and imaging to diagnose NASH.


Condition or disease
Nonalcoholic Fatty Liver Disease Nonalcoholic Steatohepatitis

Layout table for study information
Study Type : Observational
Estimated Enrollment : 110 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Non-invasive Diagnosis of Non-alcoholic Steatohepatitis in Patients With Non-alcoholic Fatty Liver Disease Using Markers and Imaging Techniques
Study Start Date : April 2016
Estimated Primary Completion Date : October 2017
Estimated Study Completion Date : December 2017


Group/Cohort
NASH
No NASH



Primary Outcome Measures :
  1. Non-invasive tool to diagnose NASH (based on imaging (TE/MRI) an markers (biochemical, volatile organic compounds) [ Time Frame: once enough evaluable patients are recruited, an average of 1 year ]

Biospecimen Retention:   Samples Without DNA
Blood, exhaled air, feces


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Subjects with proven NAFLD by histology or NAFLD proven by imaging, who are undergoing surgery (i.e. bariatric surgery or cholecystectomy) will be asked to participate in this study. Furthermore, all subjects have to be between 18 and 65 years old.
Criteria

Inclusion Criteria:

  • NAFLD proven by imaging
  • Age 18-65 years

Exclusion Criteria:

  • Incompetent to understand and/or sign the informed consent.
  • Ethanol consumption exceeding more than 14 standard beverages per week for males and more than 7 standard beverages per week for female.
  • Causes for secondary hepatic fat accumulation such as significant alcohol consumption, medications, Wilson's disease, viral infections, starvation or parenteral nutrition, among others, and conditions associated with microvesicular steatosis
  • Not willing to be informed about unexpected findings by MRI and histopathologic evaluation of liver biopsy
  • Unwilling to collect biosamples.
  • Pregnancy and breastfeeding.
  • Diagnosis of liver cirrhosis and/or hepatocellular carcinoma.
  • Current diagnosis of extrahepatic malignancie(s) or prior diagnosis within last 5 years.
  • Diagnosis of chronic inflammatory disease (i.e. inflammatory bowel disease, rheumatoid arthritis, inflammatory lung disease, severe infectious diseases), other than NAFLD/NASH
  • Chronic use of immunosuppressants (e.g. biologicals, prednisolone, azathioprine)

Layout table for additonal information
Responsible Party: Ger Koek, MD, PhD, Maastricht University Medical Center
ClinicalTrials.gov Identifier: NCT02717000     History of Changes
Other Study ID Numbers: 15-T-167
First Posted: March 23, 2016    Key Record Dates
Last Update Posted: March 23, 2016
Last Verified: March 2016

Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Digestive System Diseases